Clay B. Siegall is an influential figure in the oncology industry. Siegall established an institution known as Seattle Genetics in the year 1998, and he serves as the chairman and president. Clay Siegall is a scientist by training, and he specializes in cancer therapies. His passion for helping people with cancer motivated him to start Seattle Genetics.
Under his leadership, Seattle Genetics has done quite well. The company has developed several antibodies to treat cancer. One of the drugs from the company known as Adcetris has done very well on the international platform, and it being used in more than 65 nations. The company recently announced its plans to introduce better and affordable cancer treatment in the next five years.
As the chief executive and president of Seattle Genetics, Clay Siegall has entered into several strategic licenses for the ADC technologies. Some of the licenses have been signed with companies such as GlaxoSmithKline, AbbVie, Genentech and several others. Before starting the successful company, Siegall was working at an institution known as Bristol-Myers Squibb Pharmaceutical Research Institute. Clay also served in the national cancer institute, Alder BopPharmmaceutical, and several other establishments.
Dr. Clay Siegall has received several awards because of his achievements. In 2013, the successful scientist was given the prestigious University of Maryland Alumnus of the Year Award in Math, Computer, and Natural Sciences. Apart from his achievements at Seattle Genetics, Clay Siegall has authored over 70 publications. At the moment, Siegall also holds 15 patents. His educational background has played a fundamental role in his success too.
In an interview, Clay says that the idea of starting Seattle Genetics was born because of his passion for helping patients. When he was 19 years old, Clay’s father got cancer, and he watched it progress until he died. At the time of his death, Clay was still in school, and he understood the limited tools available to physicians who cure the disease. Because he wanted to improve the tools needed for cancer treatment, he went for his doctorate from the well-known George Washington University. While studying at the school, he learned the basics required to start the oncology company.